Kazia Therapeutics (KZIA) Capital Expenditures (2016)

Kazia Therapeutics (KZIA) posted Capital Expenditures of -$6997.5 for Q4 2016.

Kazia Therapeutics (KZIA) Capital Expenditures (2016) Analysis & Trends

Kazia Therapeutics' Capital Expenditures history runs 1 years deep, the most recent figure standing at -$6997.5 for Q4 2016.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capital Expenditures (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -8,939.03
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 43.25 Mn
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 133.40 Mn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 230.60 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - 786,000.00
10 Kazia Therapeutics 4.11 Mn 4.11 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2016 -6,997.48
Dec 31, 2016 -6,997.48